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Abstract: Some of the most successful pathogens of
human, such as Mycobacterium tuberculosis (Mtb), HIV, and
Leishmania donovani not only establish chronic infections
but also remain a grave global threat. These pathogens
have developed innovative strategies to evade immune
responses such as antigenic shift and drift, interference
with antigen processing/presentation, subversion of
phagocytosis, induction of immune regulatory pathways,
and manipulation of the costimulatory molecules. Costi-
mulatory molecules expressed on the surface of various
cells play a decisive role in the initiation and sustenance of
immunity. Exploitation of the ‘‘code of conduct’’ of
costimulation pathways provides evolutionary incentive
to the pathogens and thereby abates the functioning of
the immune system. Here we review how Mtb, HIV,
Leishmania sp., and other pathogens manipulate costi-
mulatory molecules to establish chronic infection. Impair-
ment by pathogens in the signaling events delivered by
costimulatory molecules may be responsible for defective
T-cell responses; consequently organisms grow unhin-
dered in the host cells. This review summarizes the
convergent devices that pathogens employ to tune and
tame the immune system using costimulatory molecules.
Studying host-pathogen interaction in context with
costimulatory signals may unveil the molecular mecha-
nism that will help in understanding the survival/death of
t h ep a t h o g e n s .W ee m p h a s i z et h a tt h ev e r ys a m e
pathways can potentially be exploited to develop
immunotherapeutic strategies to eliminate intracellular
pathogens.
Introduction
The immune system is highly evolved to combat and eliminate
pathogens. However, some pathogens can successfully subvert the
host immune system to establish their intracellular survival via
strategies such as the disguise or sequestration of antigens,
molecular mimicry, immunosuppression, circumvention of com-
plements and cytokines cascade, blockade of antigen presentation,
escape from apoptosis and autophagy, and modulation of
costimulatory signals [1].
T cells and antigen-presenting cells (APCs) play crucial roles in
eliminating intracellular pathogens. The optimal activation of
naive T cells is achieved by occupancy of T-cell receptor (TCR) by
the peptide-MHC complex displayed on the surface of APCs,
delivery of costimulatory signals, and the presence of proinflam-
matory cytokines [2]. The expression of costimulatory molecules
on APCs is critical in shaping the extent and nature of the immune
response. Thus, an encounter of T cells with peptide-MHC can
result in two discrete events: (a) T-cell proliferation and
differentiation into effector cells; (b) or anergy or apoptosis. The
question of which of these outcomes transpires is determined by
the delivery of appropriate costimulatory signals [3]. An array of
costimulatory molecules is displayed on the surface of APCs
(CD80/B7-1, CD86/B7-2, CD83, CD40, PDL-1, DC-SIGN, 4-
1BBL, etc.) and T cells (CD28, CTLA-4, CD40L, PD-1, OX40, 4-
1BB, etc). The level of the expression of the costimulatory
molecules may play an important role during the course of acute
disease and its remission or relapse. Hence, modulation of these
molecules by pathogens can help them to establish their existence
in the host.
Here we elaborate the mechanism by which pathogens such as
Mtb, HIV, and Leishmania sp., employ molecules viz. CD28, CD40,
CD40L, CD80, CD86, CTLA-4, PD1, PDL-1, etc., to break the
code of costimulation to establish chronic infection. The organisms
in consideration are representatives of successful pathogens from
the class of bacteria, virus, and parasites. It appears that these
pathogens adopt a common evolutionarily convergent mechanism
to evade host immune reaction. This review provides insights into
the mechanism by which pathogens suppress host immunity by
modulating the expression of costimulatory molecules. We also
suggest avenues of therapeutic intervention by exploiting costimu-
latory pathways for treating infections.
The Paradigm Shift in the Biology of
Costimulation
The unilateral ‘‘help to T-cell’’ lymphocentric paradigm of
costimulatory pathways has currently evolved into a bilateral
signaling model that influences the activity of both T cells and
APCs during their interaction (Figure 1) [4,5]. Costimulatory
molecules of CD80/CD28, tumor necrosis factor (TNF)/TNFR,
and TIM superfamilies have unmasked the plethora of the possible
ligand-receptor interactions that has expanded the understanding
of regulation of the immune responses mediated by APCs and T
cells. For example, a positive regulator like CD40L (on T cells)
when associated with CD40 (on APCs), not only activates T cells
but also results in the activation of dendritic cells (DCs); a process
that is popularly called ‘‘T-cell licensing’’ [6]. Similarly, ligation of
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interleukin-6 (IL-6) and interferon-c (IFN-c) by DCs and
activation, proliferation, and differentiation of B cells [5,7,8]. It
is reported that 4-1BBL expressed on DCs, binds to 4-1BB on T
cells, to bolster DCs help to T cells [9]. Many reports have
highlighted the inhibitory roles of CTLA-4 (CD152) and PD-1
(expressed on T cells) with ligands CD80/CD86 and PDL-1/
PDL-2 (on APCs), respectively [10,11]. It clearly suggests that
costimulation not only amplifies the magnitude of the activation of
T cells and APCs, but fine tunes the immune response as well,
thereby controlling the hyperactivation.
Modulation of Costimulatory Molecules by
Bacteria
Intracellular pathogens like Mtb, Mycobacteria avium, M. leprae,
Salmonella typhi (S. typhi), Helicobacter pylori (H. pylori), etc., infect both
macrophages and DCs. These cells recognize bacterial compo-
nents known as pathogen-associated molecular patterns (PAMPs)
through their pathogen recognition receptors (PRRs). This triggers
innate immunity that initiates antimicrobial defense mechanisms
involving autophagy, apoptosis, release of antimicrobial com-
pounds like IFN-c and TNF-a, etc. [12]. It is followed by
activation of adaptive immunity. The adaptive immune response,
personified by specificity and memory, involves the clonal selection
of B cells and T cells that confer humoral immunity (HI) and cell-
mediated immunity (CMI) to pathogens, respectively. Pathogen-
specific Th1 cells release cytokines, especially IFN-c and TNF-a,
which plays an imperative role in activating infected macrophages
and restraining the microbial growth [13]. Further, ligation of
CD80/CD86 with CD28 is essential for preventing apoptosis in T
cells [7,14]. Moreover, CD40/CD40L interaction results in
efficient IL-12 production together with an upregulation of
costimulatory molecules, in addition to enhanced antigen presen-
tation by APCs thereby leading to a boosted T-cell response
(Figure 1) [6,15]. Hence, interference in the down-modulation of
any of these pathways by the pathogens would be detrimental to
the host.
Mtb is one of the most successful pathogens in the history of
mankind. There are numerous reports indicating the role of
mycobacteria in downregulating the expression of CD80, CD86,
and CD40 on APCs [16,17]. A recent study showed, albeit for
BCG, that MHC-II, CD80, CD86, and CD40 are down-tuned
during chronic phase of infection [16]. In such studies, it is
important to delineate the expression of these molecules on
infected versus non-infected cells, as by-stander inflammation
could interfere in the interpretation of results. An elegant study
demonstrated that the expression of costimulatory molecules and
MHC are downregulated in macrophages infected with fluores-
cent reporter bacteria [16,18]. In contrast, others suggested the
augmentation of costimulatory molecules upon infection [19]. This
discrepancy may be primarily dependent on the strain, system, or
time-point of the study.
Downregulation of CD80/CD86 or upregulation of CTLA-4 by
bacteria on APCs may induce anergy/apoptosis of interacting T
cells [20,21]. Defect in this signaling pathway is known to paralyze
the release of IL-2, which may compromise the generation of T-
cell memory [22]. Impediment in CD28 signaling interferes in
IFN-c production and hence promotes the survival of pathogens.
It has been reported that M. leprae obstructs CD28/B7 signaling
pathway for rendering antigen-specific T cell unresponsive in
lepromatous leprosy patients [21]. Recently, the importance of
CD80/CD86 in controlling mycobacterial infection has been
demonstrated in CD80/CD86 double knockout mice [23]. The
down-modulation of CD80/CD86 in chronic phase of the
infection suggests that mycobacteria may actively exploit this
pathway to anergize the T cells (Figure 2). Protective CMI is
always associated with the release of chemokines and migration of
Figure 1. Immune response against intracellular pathogens. (A) PRRs of APCs sense pathogens that result in the activation of APCs. (B) This
leads to enhanced antigen presentation, upregulation of costimulatory molecules, and secretion of proinflammatory cytokines that promote the
activation of T cells. The activated T cells help in elimination of the pathogens. (C) Engagement of costimulatory molecules on APCs by T cells also
results in ‘‘bidirectional signaling’’ that activates APCs to restrict the growth of pathogens.
doi:10.1371/journal.ppat.1002676.g001
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secretion by interfering with the CD28-B7 signaling pathway
thereby obstructing the surveillance of immune cells and
enhancing the propagation of the bacterium [24,25]. It has been
shown that the most abundant cell wall lipid trehalose 6, 69-
dimycolate (TDM) of Mtb and MTSA-10 inhibit the expression of
costimulatory molecules on the surface of the macrophages
[26,27]. Similarly, CD40-CD40L interaction is very important
in mediating efficient protection against mycobacteria [28].
Indeed, it has been shown in vitro and in lepromatous patients
that CD40 is downregulated by M. leprae [29,30]. There is indirect
evidence indicating the involvement of Mtb manipulating CD40/
CD40L expression. In humans, CD40L expression on Th1 cells of
tuberculosis (TB) patients has been correlated with the intensity of
IFN-c secretion [31]. However, CD40 but not CD40L knockout
mice are susceptible to Mtb infection [32,33]. It is reported that the
heat shock protein 70 (HSP70) of Mtb acts as an alternate ligand
for CD40. Corroboratively, over-expression of HSP70 interferes
with long-time persistence of Mtb and allows its clearance [34].
Interestingly, in chronic mycobacterial infections, CD40 is
suppressed on infected cells [16]. Therefore, it is intriguing to
speculate that in the chronic phase of infection, mycobacteria may
hamper CD40 expression or manipulate CD40L signaling through
binding with HSP70 instead of CD40L in order to evade host
defense mechanisms.
Mycobacteria can upregulate the expression of PD-1 and its
ligands PDL-1/PDL-2 [35]. Several studies have shown that T
cells and natural killer (NK) cells from TB patients have increased
PD-1 expression [36,37]. Blockade of PD-1 interaction with PDL-
1/PDL-2 enhances immune response. These observations suggest
that mycobacteria may exploit PD-1 and PDL-1/PDL-2 pathways
to dampen the host immune responses. In contrast, some studies
have suggested that these pathways may be involved in controlling
exuberant T-cell responses in TB and hence may be beneficial for
both the host and the pathogen [36,38,39]. Mtb retards the
development and maturation of monocyte-derived DCs to limit
the immune response [40]. These immature DCs have a
tolerogenic effect in vivo that can result in the generation of
regulatory T cells (Tregs). Tregs can restrain the proliferation of
naive and memory T cells, thereby suppressing pre-existing T-cell
immunity [41,42].
Besides mycobacteria, many other pathogens can exploit
CD80/CD86-CD28/CTLA-4 pathways for their persistence
(Table 1). H. pylori causes chronic infection in the gut resulting
in peptic ulcers. Further, it is known to induce the expression of
CTLA-4, resulting in the anergy of T cells and poor clearance of
the bacteria [43]. Yersinia pseudotuberculosis decreases CD86
expression on B cells and impedes the function of both B cells
and T cells [44]. S. typhi is known to suppress ICAM-1 and as a
consequence reduces the antigen uptake by APCs and inadequate
T-cell response [45,46]. H. pylori diminishes the expression of
CD40L on T cells and therefore employs CD40/CD40L pathway
for its survival. Furthermore, it upregulates PDL-1 expression on
gastric epithelial cells and inhibits the activation of T cells
recruited to gastric mucosa [47]. In addition, it has been reported
that PDL-1 upregulation not only blocks T-cell proliferation and
IL-2 secretion, but also promotes the development of Tregs [48].
Bordetella pertussis and B. bronchiseptica decrease the manifestation of
CD40 and ICAM-1 on DCs, and subsequently, render DCs
tolerogenic and promote chiefly Tregs but not Th1 cells [49,50].
Hence, costimulatory molecules could serve as attractive targets
for bacteria to modulate in order to prolong their own survival.
Figure 2. Pathogens modulate the expression of costimulatory molecules for their survival. Sensing of pathogens through PRRs triggers
the activation of APCs. (A) Costimulatory molecules, which act as the second signal for T-cell activation, are upregulated on infected cells. Persistence
of intracellular pathogens modulates the expression of costimulatory molecules, such as downregulation of CD40/CD80/CD86 and upregulation of
PDL-1 on infected APCs. Similarly, retarding the exhibition of CD28/CD40L augments PD-1/CTLA-4 on T cells. (B) Interaction of T cells with the
infected APCs impairs the function of T cells by inducing anergy, apoptosis, or exhaustion. (C) Lack of T-cell help impedes the activity of APCs,
eventually enhancing the survival of pathogens.
doi:10.1371/journal.ppat.1002676.g002
PLoS Pathogens | www.plospathogens.org 3 June 2012 | Volume 8 | Issue 6 | e1002676Modulation of Costimulatory Molecules by
Viruses
To counter viral infestation, the vertebrate immune system has
evolved complex antiviral innate and adaptive immune mecha-
nisms. Some of the spectacular examples to limit viral replication
by the host cells are the production of interferons, NK cell-
mediated lysis, and apoptosis of the infected cells [51,52]. Adaptive
antiviral immunity relies greatly on the lysis of infected cells by
cytotoxic CD8
+ T cells and neutralizing antibodies secreted by B
cells.
HIV is a retrovirus that is responsible for 1.9 million deaths
annually [53]. It predominantly infects CD4
+ T cells. Further, it
invades DCs, monocytes, and macrophages expressing CD4 and
one of its coreceptors CCR5 or CXCR4 [54]. Additionally, HIV
can bind to DC-SIGN and mannose receptors [55]. However, the
virus preferentially replicates in the activated HIV-specific CD4
+
T cells [56]. Indeed, excessive loss of CD4
+ T cells is the hallmark
of HIV infection [57]. Like many other intracellular pathogens,
HIV efficiently exploits the costimulatory molecules to override
the immune responses. Its infection is associated with decreased
expression of CD40L on CD4
+ T cells [58]. Upon activation,
CD4
+ T cells from individuals with progressive disease show very
little upregulation of CD40L, which corroborates with their
inability to help APCs and failure to induce IL-12 in DCs [59].
Further, CD40-CD40L interaction has been demonstrated to be
important in engendering a robust HIV-specific CD8
+ T-cell
response. Furthermore, HIV interferes in the CD40 signaling
pathway in B cells and hinders T cell help, thereby impairing the
secretion of IgG and IgA antibodies [60,61]. AIDS patients suffer
from a defective humoral immunity, which may be due to loss of
T-cell function, or B-cell intrinsic defects [62,63]. HIV upregulates
Fas and FasL (members of TNF superfamily) on CD8
+ T cells and
APCs, respectively, which leads to the apoptosis of the interacting
CD8
+ T cells [64,65]. Thus, in HIV infections, the hunter
becomes the hunted!
During viral infections, continual expression of CD80/CD86 on
DCs is decisive to maintain the effector function of CD8
+ T cells
[66]. Intriguingly, HIV downregulates the expression of CD80/
CD86 and their ligand CD28 on infected APCs and T cells,
respectively [67,68]. The expression of costimulatory molecules
such as 4-1BBL, CD70, OX40, and OX40L is affected during
HIV-1 infection [9,69]. Measles, herpes, and hepatitis C viruses
(HCV) retard the expression of CD80, CD86, CD25, CD83, and
CD40 that leads to poor CD8
+ T-cell priming [70–72]. In
addition, Herpes virus suppresses ICAM-1 on APCs, thereby
obstructing immunological synapse with T cells [73].
Chronic viral infections are associated with loss of function in T
cells, a phenomenon popularly known as T-cell exhaustion.
Exhausted T cells highly express PD-1 and have poor effector
function [74]. PD-1 expression on HIV-specific T cells is
associated with T-cell exhaustion and disease progression [75].
PD-1 is known to make CD8
+ T cells more susceptible to Fas-
mediated lysis [76]. Signaling through PD-1 can suppress IL-2
secretion by CD8
+ T cells. IL-2 is known to rescue T cells from
anergy and boost the memory response [77]. In addition,
upregulation of PDL-1 on APCs during HIV or hepatitis B virus
(HBV) infection supports the survival of pathogens (Table 1)
Table 1. Exploitation of costimulatory molecules by intracellular pathogens.
Intracellular Pathogens Costimulatory Molecules Loss of Function References
Bacteria
M. tuberculosis CD80Q, CD86Q, CD40Q,
PDL-1/PDL-2q, PD-1q
Hampers effective T-cell activation. Induces anergy or
apoptosis in T cells, paralyzes IL-2 and chemokines secretion,
and inhibits NK cell function.
[16,20,35,37]
M. leprae CD80Q, CD28Q Blockade of IL-12 secretion, defective T-cell response [21]
S. typhimurium ICAM-1Q Impedes antigen uptake ability of APCs [45,46]
B. anthracis CD40Q, CD80Q, CD86Q Impairment of antigen specific B-cell and T-cell immunity,
suppresses the function of DCs
[104,105]
H. pyroli PDL-1q, CTLA-4q Exhaustion of DCs, obstructs cytokines secretion, induces
anergy in T cells
[43,106]
B. bronchiseptica CD40Q Hampers maturation of DCs [49]
B. pertussis CD40Q,I C A M Q Promotes differentiation of Tregs [50]
Viruses
HIV PD-1q, PDL-1q, CTLA-4q, CD80Q,
CD86Q, CD33Q, CD40LQ, 4-1BBQ,
OX40Q
Blocks IL-2 but augments IL-10 secretion, induces exhaustion
of T cells, defective CTLs response, and hampers antigen
uptake ability of APCs
[58,60,69,75]
HBV PDL-1q, PD-1q Induces IL-10 secretion, enhances apoptosis and anergy in T cells [79]
HCV CD83Q, CD86Q Reduces stimulatory capacity of DCs [72]
Measles CD40Q, CD80Q, CD86Q, CD25Q,
CD83Q, CD69Q
Abnormal DCs differentiation, improper CD8 T-cell proliferation [70]
Herpes simplex virus ICAM-1Q Blocks APCs T-cell communication [71,73]
Protozoans
L. donaovani CD80Q Inefficient T-cell response [81,107]
T. gonodii CD80Q Inhibits T-cell stimulatory activity [82]
q,upregulation;
Q, downregulation.
doi:10.1371/journal.ppat.1002676.t001
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restraining the function of both T cells and APCs.
Modulation of the Expression of Costimulatory
Molecules by Intracellular Protozoan Parasites
T cells play a significant role in controlling the protozoa-
inflicted diseases like malaria, visceral leishmaniasis, and trypano-
somiasis. Humoral responses play a less important role. However,
complement-mediated killing or opsonization is responsible for
control of pathogen during the intermittent extracellular phase of
its replication cycle within the vertebrate host [80].
Parasites like Leishmania donovoni, L. chagasi, Toxoplasma gonodii (T.
gonodii), T. cruzi, and Plasmodium falciparum can manipulate the
costimulatory molecules for evading immune system. L. donovani
and L. chagasi infect macrophages and are reported to downreg-
ulate both CD80 and ICAM-1 [21,81]. Such APCs fail to
optimally activate T cells. T. gondii and T. cruzi, selectively dampen
the exhibition of CD80 and CD28, respectively to impair the
function of T cells [82]. CD40-CD40L signaling is crucial for Th1
immunity against L. major, because CD40L/CD40 knockout mice
sparsely secrete IL-12, favoring Th2-biased response [83,84].
Interestingly, L. major can differentially modulate the expression of
CD40 and thus anergizes T cells and promotes Tregs population
[83]. Plasmodium interferes in the signaling mechanism of CD40 in
DCs [85]. CD40 deficient mice succumb to plasmodium infection.
This signifies that this pathway is detrimental in providing
sterilizing immunity to parasites, as it activates APCs and
protective Th1 responses. In conclusion, parasites can efficiently
empower the immune system by dampening the expression of
costimulatory molecules.
Mechanism Involved in Immunomodulation of
Costimulatory Molecules
Inductionoftheexpressionofcostimulatorymoleculesonexposure
to various inflammatory cytokines (IL-6, IL-12, TNF-a,I F N - c)o r
PAMPS/DAMPsisregulated bytranscription factorssuch asNF-kB,
IRF-3, AP-1, NFAT [86,87]. Activation of these transcription factors
is tightly regulated by various kinases or phosphatases that include
mitogen-activated protein kinases (MAPKs), TNF receptor-associat-
ed factor proteins (TRAF), IL-1 receptor-associated kinase 4
(IRAK4), phosphoinositide 3-kinase (PI3K), and Janus-kinase. For
example, triggering of TLR-4 with lipopolysaccharides (LPS) elicits
pathways dependent on myeloid differentiation primary response
gene 88 (MyD88) and TIR-domain-containing adapter-inducing
interferon-b (TRIF). Both the molecules induce downstream
signaling to activate MAPKs, NF-kB, and IRF family proteins,
which are responsible for the enhanced expression of CD40 and
CD86 [86,88]. Further, T-cell interaction with APC involving TCR
and costimulatory molecules activates a plethora of downstream
signaling molecules, leading to the induction of the expression of
CD40L, PD-1, and CD28 [89,90].
Intracellular pathogens utilize an array of mechanisms to
manipulate costimulatory molecules. Upon infection, pathogens
trigger IL-10 secretion by inhibiting p38MAP kinases and
promoting ERK phosphorylation [91]. IL-10 blocks the degrada-
tion of IkB-a that inhibits the NF-kB activation eventually
inhibiting the expression of costimulatory molecules [92]. Inter-
ference in TLRs signaling by the intracellular pathogens is
considered to be a foremost event in the suppression of
costimulatory molecules. Mannosylated lipoarabinomannan
(ManLAM) of Mtb binds to DC-SIGN and compromises the
LPS-induced activation of DCs by interfering in the TLRs’
signalling [93]. Binding of Mtb early secreted antigenic target
protein 6 (ESAT-6) to TLR-2 activates AKT and prevents
interaction between the MyD88 and IRAK4, consequently
abrogating NF-kB activation that suppresses CD80 expression
[94]. Similarly, HIV upregulates PDL-1 on DCs and monocytes
by attenuating the signaling of TLR-7 and TLR-8 [95]. In
addition, HIV-mediated PI3K activation upregulates PDL-1 on
APCs and thus suppresses the activation of HIV-specific CD8
+ T
cells [96]. Rapid endocytosis of costimulatory molecules upon
infection is suggested as one of the mechanisms to interrupt the
function of APCs. For instance, Nef protein of HIV modulates the
actin-dependent trafficking mechanism to remove CD80/CD86
from the monocytes surface, making them inefficient to activate T
cells [97].
TCR signaling is central for the optimum expression of
costimulatory molecules and effector function of T cells. There-
fore, it may serve as an important target for pathogens to paralyze
T-cell activity [98]. Mtb glycolipids interfere with TCR signaling
and block the activation of CD4
+ T cells [99]. HIV gp120
interacts with CD4 (a coreceptor for TCR) that inhibits
intracellular signal transduction through TCR, leading to
decreased hydrolysis of polyphosphoinositide (PI), Ca
2+ influx,
activation of protein kinase C (PKC), and eventually failure of
NFAT translocation. These events culminate in the inhibition of
CD40L expression. Decline of CD40L on T cells abrogates the
bidirectional signaling and reduces the exhibition of CD80 on
APCs [100]. In contrast, Nef activates NFAT and stimulates IL-2
release to overcome the exogenous requirement of IL-2 to
promote T-cell proliferation, consequently disseminating the
infection [101]. However, Nef retards CD28 and CD4 expression,
thereby making T cells incapable of promoting CMI [98].
Corroborative with these observations, Nef-mutated HIV is
unable to cause persistent infection. Similarly, core protein of
HCV inhibits TCR signaling and upregulates PD-1 [102]. The
above-mentioned mechanisms imply that pathogens can effectively
utilize various costimulatory pathways to subvert immune response
to persist in the host.
Therapeutic Implications
The noncompliance with the relatively high dose and extended
therapeutic regime reduces the effectiveness of current drugs,
leading to global emergence of MDR/XDR/TDR pathogenic
strains. Interestingly, costimulatory molecules have been suggested
for therapeutic intervention to treat lymphoma patients [4,103].
To develop alternative or adjunct (with drugs) therapies, an
intensive effort has been undertaken in last decade to understand
how intracellular pathogens exploit costimulatory molecules,
which are the tour de force of the immune system [27,31,68,78].
The potent role of costimulatory molecules is aptly established in
the optimum activation of T cells and APCs; the cells that play a
cardinal role in curbing the infections. Hence, immunotherapy
involving costimulatory molecules can be a breakthrough strategy
to treat various diseases, minimizing side effects inflicted by drug
therapies and in restricting the emergence of drug resistance.
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